BUZZ-Street View: All eyes on Pfizer's pipeline, obesity drug update

Pfizer PFE.N on Tuesday beat Wall Street estimates for fourth-quarter profit driven by cost cuts and steadier COVID vaccine sales

PFE has been looking to show investors steadier execution and growth after large swings related to its COVID-19 vaccine

OBESITY DATA IS 'LITMUS TEST' FOR PIPELINE

BMO Capital Markets ("Outperform", PT: $38) says Pfizer continues to execute the plan outlined for investors in what is shaping up to be a manageable macro and political environment

J.P Morgan ("Neutral", PT: $30) says that while it sees several assets in PFE's pipeline (particularly in oncology) that could make the story more interesting, further progress is necessary to change the narrative on shares

Guggenheim Partners ("Buy", PT: $33) says data from Pfizer's experimental obesity drug, danuglipron, will be a "litmus test for the company's pipeline productivity"

Leerink ("Market Perform," PT: $28) says "management is executing well and delivering results above expectations, but we await future pipeline developments"